The chimeric proteins which result from CBF AML fusion genes function as dominant negative inhibitors of the CBF transcription factor, composed of RUNX1 and CBFβ, which are essential for normal myeloid cell development. This evidence concerns the gene RUNX1 and acute myeloid leukemia.